Open Your FREE Demat Account Now!

Astal Laboratories Ltd. Share Price

NSE
BSE

BSE : 512600

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Low

₹

High

₹

Price Summary

Previous Close ₹59.90
Day's Range ₹56.31 - ₹60.49
Open ₹59.98
52 Week Range ₹49.99 - ₹99.90
Volume 45,419
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 27.21
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 17.41
TTM EPS (₹) 3.36
P/E Ratio 18.76
Book Value(₹) 0.74
PAT Margin (%) 5.88
Face Value (₹) 10.00
ROCE(%) 9.15

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 253.27 642.31
Expenses N/A N/A
PBT 27.93 119.77
Operating profit 0.0 0.0
Net profit 20.9 89.25

Shareholding Pattern

Promoters (% Holding)

4.59%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

95.41%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

0.00%

About Astal Laboratories Ltd.

Founded 1993

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,26,121.89 1,828.55 1,583.70 - 1,583.70
Divi's Laboratories Ltd. 2,66,424.27 10,158.50 5,647.50 - 5,647.50
Torrent Pharmaceuticals Ltd. 1,79,914.00 4,718.50 3,532.60 - 3,532.60
Laurus Labs Ltd. 1,24,601.40 2,340.30 917.95 - 917.95
Apollo Hospitals Enterprise Ltd. 1,23,324.10 8,385.00 6,696.50 - 6,696.50
Lenskart Solutions Ltd. 1,20,217.91 722.00 0.00 - 0.00
Zydus Lifesciences Ltd. 1,18,702.96 1,196.15 835.50 - 835.50
Dr. Reddy's Laboratories Ltd. 1,14,599.26 1,366.95 1,101.00 - 1,101.00
Cipla Ltd. 1,13,112.41 1,396.75 1,165.70 - 1,165.70
Mankind Pharma Ltd. 1,04,630.52 2,502.50 1,909.70 - 1,909.70
no-content No Records Found

Latest News

Nov
5
2026
EQUITY Posted on Nov 5th 2026

Centenial Surgical Suture informs about board meeting

Centenial Surgical Suture has informed that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026, to approve Standalone Un-Audited Financial Results for the quarter & half year ended on September 30, 2026, pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015; to consider the proposal for raising of funds by way of equity shares or any other securities through permissible modes, including but not limited to a rights issue or preferential issue or qualified institutions placement or any other method or a combination thereof, as may be permitted under applicable laws including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, as amended, and subject to receipt of regulatory / statutory / necessary approvals, as may be required; and any other business with the permission of chair.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
5
2026
EQUITY Posted on Nov 5th 2026

Krishna Institute of Medical Sciences informs about press release

Krishna Institute of Medical Sciences has informed that it enclosed a copy of the newspaper publication on the unaudited (Standalone and Consolidated) financial results of the company for the 02nd quarter and half-year ended 30th September 2026, published in Financial Express (English) and Navatelangana (Telugu). The said publication may also be accessed on the website of the company, https://www.kimshospitals.com/investors/Disclosures under Regulation 46 of SEBI (LODR) Regulations, 2015/ Newspaper advertisements.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
5
2026
EQUITY Posted on Nov 5th 2026

Gujarat Kidney and Super Speciality inform about investor presentation

Further to intimation dated October 28, 2025, Gujarat Kidney and Super Speciality has submitted copy of the presentation. It is also disclosed on the website of the Company and is available on the below link: https://manage.gujaratsuperspecialityhospital.com/uploads/OtherImages/1793809082319_Investor%20pre sentation%2005112026.pdf
The above information is a part of company’s filings submitted to BSE. 
Read More
Nov
5
2026
EQUITY Posted on Nov 5th 2026

Hester Biosciences informs about outcome of board meeting

With reference to letter dated 27 October 2026 intimating the date of the Board Meeting for consideration of the standalone and consolidated financial results for the quarter and six months period ended 30 September 2026 and pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hester Biosciences has informed that Board of Directors, in their Meeting held today, have approved Unaudited Standalone and Consolidated Financial Results for the quarter and six months period ended 30th September 2026, as recommended by Audit Committee; Unsecured loan of an aggregate amount of USD 1 million to Hester Biosciences Africa Limited (Hester Africa), foreign wholly-owned subsidiary in Tanzania, in one or more tranches. The loan is being extended for business and general corporate purposes, working capital requirement etc., subject to compliance with the applicable laws. They attached the approved unaudited standalone and consolidated financial results and limited review reports; and a Press Release issued in this regard. The details in this regard, pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, is enclosed as Annexure A. They will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board Meeting commenced at 10:30 am (IST) and concluded at 11:05 am (IST).
The above information is a part of company’s filings submitted to BSE. 
Read More
Nov
5
2026
EQUITY Posted on Nov 5th 2026

Lenskart Solutions informs about audio recording of earnings call

With reference to its letter dated October 22, 2026 filed with the stock exchanges and in terms of Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lenskart Solutions has informed that it enclosed the web link for the audio recording of the Earnings Call, conducted on November 4, 2026 to discuss the Financial Results for the quarter and half-year ended September 30, 2026. The above information will also be hosted on the Company’s website: https://www.lenskart.com/corporate/investorrelations.

The above information is a part of company’s filings submitted to BSE. 

Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Astal Laboratories Ltd. ?

The current share price of Astal Laboratories Ltd. is ₹59.90 as of 2026-11-05.

The market capitalisation of Astal Laboratories Ltd. is ₹256.09 as of 2026-11-04.

The 1-year return of Astal Laboratories Ltd. is -37.00% as of 2025-11-04.

The P/E ratio of Astal Laboratories Ltd. is 18.76 as of 2026-11-05.

The 52-week high and low of Astal Laboratories Ltd. are ₹99.90 and ₹49.99, respectively, as of 2026-11-05.

The dividend yield of Astal Laboratories Ltd. is 0.0% as of2026-11-04.

You can buy Astal Laboratories Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Astal Laboratories Ltd. is .

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore